Evidence map›Paper›PMID 41876462›Full record

ArticleCell death & disease2026

Metabolic orchestration driven by GGCT: diverting glutamine to glutathione biosynthesis while enhancing glucose anaplerosis for tumor proliferation.

Lijun Yang, Handi Sun, Ruonan Wang, Depeng Yang, Qi Gu, Guiping Zhao, Liping Sun, Xinghe Chen, Jianxin Lv, Xiaoyu Lin and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Lijun Yang *School of Life Science and Technology, Harbin Institute of Technology, Harbin, China.
Handi Sun *School of Life Science and Technology, Harbin Institute of Technology, Harbin, China.
Ruonan Wang *School of Life Science and Technology, Harbin Institute of Technology, Harbin, China.
Depeng Yang *School of Life Science and Technology, Harbin Institute of Technology, Harbin, China.
Qi Gu *School of Life Science and Technology, Harbin Institute of Technology, Harbin, China.
Guiping ZhaoSchool of Life Science and Technology, Harbin Institute of Technology, Harbin, China.
Liping SunSchool of Life Science and Technology, Harbin Institute of Technology, Harbin, China.
Xinghe ChenSchool of Life Science and Technology, Harbin Institute of Technology, Harbin, China.
Jianxin LvSchool of Life Science and Technology, Harbin Institute of Technology, Harbin, China.
Xiaoyu LinNational Key Laboratory of Immunity and Inflammation, Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Suzhou, China.
Jiahui ChengSchool of Life Science and Technology, Harbin Institute of Technology, Harbin, China.
Muhammad Luqman AkhtarSchool of Life Science and Technology, Harbin Institute of Technology, Harbin, China.
Mengmeng ZhangSchool of Life Science and Technology, Harbin Institute of Technology, Harbin, China.
Jingyu ZangSchool of Life Science and Technology, Harbin Institute of Technology, Harbin, China.
Xinyue ShiSchool of Life Science and Technology, Harbin Institute of Technology, Harbin, China.
Zihao ZhangSchool of Life Science and Technology, Harbin Institute of Technology, Harbin, China.
Lijun DengSchool of Life Science and Technology, Harbin Institute of Technology, Harbin, China.
Lixing XiaoSchool of Life Science and Technology, Harbin Institute of Technology, Harbin, China.
Lei YueSchool of Life Science and Technology, Harbin Institute of Technology, Harbin, China.
Wei DongDepartment of Hepatobiliary and Pancreatic Surgery, Harbin Medical University Cancer Hospital, Harbin, China.ORCID http://orcid.org/0009-0006-8939-3972
Qinghua JiangSchool of Life Science and Technology, Harbin Institute of Technology, Harbin, China.
Fang HanSchool of Life Science and Technology, Harbin Institute of Technology, Harbin, China. hanfang@hit.edu.cn.
Yu LiSchool of Life Science and Technology, Harbin Institute of Technology, Harbin, China. liyugene@hit.edu.cn.ORCID http://orcid.org/0000-0003-3484-946X
Huan NieSchool of Life Science and Technology, Harbin Institute of Technology, Harbin, China. nh1212@hit.edu.cn.ORCID http://orcid.org/0000-0001-9221-1283

Funding

National Natural Science Foundation of China (National Science Foundation of China) 32270759
6 · The paper itself

Abstract

Glutamine (Gln) metabolism serves dual metabolic roles: it fuels the tricarboxylic acid (TCA) cycle, while concurrently sustaining redox balance through glutathione (GSH) synthesis. γ-Glutamylcyclotransferase (GGCT), a key metabolic enzyme frequently overexpressed in various cancers, has an undefined role in directing glutamine metabolic flux during tumorigenesis. This study demonstrated that glutamine promotes cancer cell growth by regulating GSH and reactive oxygen species (ROS) levels, with this process being closely associated with GGCT expression. Knockdown of GGCT significantly inhibited tumor growth, depleted GSH, and elevated ROS levels, whereas overexpression of GGCT exerted the opposite effects. Furthermore, we refined and established the Gln/c-Myc/miR-29b-3p/GGCT regulatory axis. Notably, GGCT knockdown markedly altered mitochondrial morphology and impaired oxidative phosphorylation and glycolysis capacity. Targeted metabolomics analysis revealed that GGCT knockdown significantly reduced the abundance of TCA cycle intermediates, while GGCT overexpression substantially increased their levels. [U-

Indexed as

gamma-GlutamylcyclotransferaseGlucoseGlutamineGlutathioneNeoplasmsAnimalsCell Line, TumorCell ProliferationCitric Acid CycleGlycolysisHumansMetabolic ReprogrammingMiceMice, NudeMitochondriaReactive Oxygen Speciesgamma-GlutamylcyclotransferaseGlucoseGlutamineGlutathioneReactive Oxygen Species

Identifiers

PMID41876462
PMCPMC13039682

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.